PolyPid Ltd., a late-stage biopharma company focused on improving surgical outcomes, is set to report its first quarter 2024 financial results and operational highlights on Wednesday, May 8, 2024. The company, listed on Nasdaq under the ticker symbol PYPD, will release this information before the opening of the U.S. financial markets.
PolyPid will also host a conference call and webcast at 8:30 AM Eastern Time on the same day to discuss the results and provide an update on its business operations. The company recommends registering at least 5 minutes before the call begins to ensure a smooth connection. For those not planning to ask questions, PolyPid suggests listening via the webcast.
PolyPid’s core technology, PLEX (Polymer-Lipid Encapsulation matriX), allows for the controlled, prolonged release of therapeutics, enabling precise delivery of drugs at optimal rates over extended periods. The company’s lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials for preventing abdominal colorectal surgical site infections. Additionally, PolyPid is in the preclinical stages of testing OncoPLEX for the treatment of solid tumors, starting with glioblastoma.
For more information about PolyPid, visit their website at www.polypid.com and follow them on Twitter and LinkedIn. The company emphasizes that any references or links to third-party websites provided in this news release are for convenience only and are not incorporated by reference.
Investors interested in PolyPid can contact Ori Warshavsky, COO – US, at 908-858-5995 or IR@Polypid.com, or Brian Ritchie at LifeSci Advisors at 212-915-2578 or Britchie@lifesciadvisors.com.